Gentian Diagnostics ASA

Oslo Stock Exchange GENT.OL

Gentian Diagnostics ASA Net Income Margin for the year ending December 31, 2023: -7.82%

Gentian Diagnostics ASA Net Income Margin is -7.82% for the year ending December 31, 2023, a 66.89% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Gentian Diagnostics ASA Net Income Margin for the year ending December 31, 2022 was -23.61%, a 20.83% change year over year.
Gentian Diagnostics ASA Net Income Margin for the year ending December 31, 2021 was -29.83%, a -19.16% change year over year.
Gentian Diagnostics ASA Net Income Margin for the year ending December 31, 2020 was -25.03%, a 69.88% change year over year.
Gentian Diagnostics ASA Net Income Margin for the year ending December 31, 2019 was -83.12%, a -93.57% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Oslo Stock Exchange: GENT.OL

Gentian Diagnostics ASA

CEO	Mr. Njaal Kind
IPO Date	Dec. 14, 2016
Location	Norway
Headquarters	Bjørnåsveien 5
Employees	58
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Medical Instruments Pharmaceuticals

Description

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.

Key trends

Past 5 years